EPHA2 and neoplasm: They are developed to target tumor-associated antigens (TAA), such as interleukin 13 receptor α 2 (IL13Rα2), epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and erythropoietin-producing hepatocellular carcinoma A2 (EphA2) [9,10].